ALX Oncology Confirms Directors at Annual Meeting

ALX Oncology Holdings ( (ALXO) ) just unveiled an announcement.

ALX Oncology Holdings Inc. held its Annual Meeting of stockholders on June 11, 2025, where several key proposals were voted upon. The election of two Class II directors, Scott Garland and Barbara Klencke, M.D., was confirmed, with both set to serve until the 2028 annual meeting. Additionally, stockholders approved the compensation of the Company’s named executive officers and ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (ALXO) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on ALX Oncology Holdings stock, see the ALXO Stock Forecast page.

Spark’s Take on ALXO Stock

According to Spark, TipRanks’ AI Analyst, ALXO is a Underperform.

ALX Oncology Holdings faces significant financial hurdles due to ongoing losses and negative cash flow, reflected in its low financial performance score. The technical analysis indicates a bearish trend with the stock trading below major moving averages. The valuation is challenging due to a negative P/E ratio and lack of dividends. Recent corporate events offer some hope with new leadership appointments, though offset by workforce reductions. Overall, the challenges outweigh the positive aspects, resulting in a low overall stock score.

To see Spark’s full report on ALXO stock, click here.

More about ALX Oncology Holdings

Average Trading Volume: 497,459

Technical Sentiment Signal: Sell

Current Market Cap: $28.53M

For detailed information about ALXO stock, go to TipRanks’ Stock Analysis page.